MedStar Authors catalog › Details for: Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.
Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma. Journal: The oncologist.Published: 2021; ; ; ; ISSN: 1083-7159.UI/PMID: 34097758.Subject(s): *Antineoplastic Combined Chemotherapy Protocols | *Lymphoma, Large B-Cell, Diffuse | Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | Cyclophosphamide/tu [Therapeutic Use] | Doxorubicin/tu [Therapeutic Use] | Humans | Lymphoma, Large B-Cell, Diffuse/dt [Drug Therapy] | Prednisone/tu [Therapeutic Use] | Prognosis | Retrospective Studies | Rituximab/tu [Therapeutic Use] | Vincristine/tu [Therapeutic Use]Institution(s): MedStar Washington Hospital Center | Washington Cancer InstituteDepartment(s): Hematology/Oncology Fellowship | Internal Medicine ResidencyActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1002/onco.13846 (Click here) ORCID: Desai, Sanjal https://orcid.org/0000-0002-7892-2625 (Click here) Abbreviated citation: Oncologist. 26(9):e1660-e1663, 2021 09; .Local Holdings: Available online from MWHC library: 1996 - present.Abstract: Outcomes of diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies. The efficacy of other regimens in transformed or concurrent DLBCL is largely unknown. In this single-center retrospective study, we present characteristics of concurrent and transformed DLBCL and outcomes after dose-adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA-EPOCH-R) comparative with de novo DLBCL. Of 170 patients with DLBCL, 136 were de novo, 17 were concurrent, and 17 were transformed. Transformed DLBCL had significantly lower complete response rates and progression-free survival (PFS) but similar overall survival (OS) compared with de novo counterpart. There was no significant difference between de novo and concurrent DLBCL regarding response rates, PFS, and OS. DA-EPOCH-R was associated with inferior OS. Thus, intensified treatment with DA-EPOCH-R might not improve outcomes of transformed DLBCL. Copyright (c) 2021 AlphaMed Press.